Hormone replacement therapy (HRT) and epidermal growth factor receptor (EGFR) single nucleotide polymorphisms (SNPs) have been reported as risk factors for lung cancer in never smokers. We investigate the interaction of EGFR SNPs and HRT for lung adenocarcinoma risk in never-smoking women. This study included 532 never-smoking female lung adenocarcinoma patients and 532 controls, with EGFR SNPs retrieved from a genome-wide association study. The associations of EGFR SNPs with the lung adenocarcinoma risk were estimated by multivariate-adjusted logistic regression. The Haploview program was used to select tagged EGFR SNPs interacted with HRT and construct haplotype blocks. The Benjamini and Hochberg method was used to reduce the multiple testing effects. Among 84 EGFR SNPs retrieved, 11 tagging EGFR SNPs showed an interaction with HRT and lung adenocarcinoma risk, which were mostly located near the tyrosine kinase domain. Eight of the tagged SNPs were in two haplotype blocks. The interactions between HRT and numbers of protective EGFR SNP genotypes are significant in both blocks (P for interaction = 0.0004 and 0.0032, respectively). A trend of decrease in lung adenocarcinoma risk was found in subjects with HRT harboring an increasing number of protective EGFR SNP genotypes in both blocks (P = 0.0032 and 0.0046, respectively). In conclusion, HRT use may modify the association of EGFR SNPs with lung adenocarcinoma risk. The EGFR SNPs have a cumulative effect on decreasing lung adenocarcinoma risk in never-smoking women with HRT use.
Introduction
Lung cancer is the leading cause of cancer deaths (1) (2) (3) . Tobacco smoking is a well-known etiologic factor for lung cancer (4) . However, it is estimated that 15% of male and 53% of female lung cancer patients were non-smoker worldwide (5) . In Taiwan, >90% of female lung cancer patients were never smokers. Among these patients, the percentage of adenocarcinoma is relatively high (75%) (6) . The etiologies of lung adenocarcinoma for never-smoking women may be different from those for smokers. To explore the potential risk factors in never smokers, especially in women, has become an important issue.
Epidermal growth factor receptor (EGFR) is important for cell proliferation, differentiation, migration, motility, resistance to apoptosis and enhancing cell survival (7) . Overexpression or structure alteration of EGFR may be related to carcinogenesis and tumor progression (8) (9) (10) . Several EGFR polymorphisms were reported to be associated with lung cancer risk (11) (12) (13) . A more recent study also reported an association between an EGFR intron 1 single nucleotide polymorphism (SNP) and lung adenocarcinoma risk in neversmoking female subjects (14) . However, the interactions between the EGFR polymorphism and the environmental factors are seldom investigated.
The association of hormone replacement therapy (HRT) and lung cancer in women has been widely studied. Population-based cohort studies in Sweden, Japan and Canada showed that HRT use was associated with an increased lung cancer risk (15) (16) (17) . In contrast, several studies have demonstrated an association between HRT use and a decreased lung cancer risk (18) (19) (20) (21) (22) (23) . These findings indicated the importance of HRT in lung carcinogenesis, especially for female.
A functional linkage between estrogen receptor and EGFR signaling pathways was reported (24) . Treating lung cancer cells with fulvestrant, an antiestrogenic drug, could lead to an increased level of EGFR (25) . The activation of nuclear estrogen receptors may be regulated by EGFR (26) . In lung adenocarcinoma patients, there is a significant correlation between estrogen receptor expression and EGFR mutations (27, 28) .
We hypothesized that there might be an interaction between EGFR polymorphisms and HRT use in lung carcinogenesis for never smokers. The inconsistent data regarding the association between HRT use and lung cancer risk may be related to genetic variation in study populations. To investigate the interaction between EGFR polymorphisms and HRT use in association with lung adenocarcinoma risk, we conducted a case-control study in never-smoking women. The EGFR SNP data were retrieved from a genome-wide association study (GWAS) on female lung adenocarcinoma in never smokers (29) .
EGFR SNP, HRT and lung adenocarcinoma risk
Control subjects were cancer-free individuals recruited from the health examination departments of the six hospitals during the same period of case recruitment.
In this study, all the subjects were recruited from the never smokers population in the GELAC study. In the original GELAC study, we defined subjects smoked cigarettes regularly for >6 months as 'ever cigarette smokers' (19, 31) . Otherwise, subjects were defined as never smokers. All the subjects were never-smoking women. The control subjects were 1:1 frequency matched to cancer patients on the basis of age. The institutional review board of each hospital approved this study.
Data collection
Informed consent was obtained from each study subject for blood sample collection and a personal interview based on a structured questionnaire. The personal interview was conducted by a trained research nurse, who collected information on age, education level, active and passive cigarette smoking, menopausal status, number of pregnancies, deliveries and miscarriages, HRT and contraceptive medication, history of cooking fume exposure and family history of malignancies.
Menopause was defined as the permanent cessation of menstrual bleeding, including natural menopause and surgical menopause. The menopausal status at recruitment and the age at menopause were also recorded. The cumulative duration of HRT and contraceptive medication was recorded. HRT use was defined as a history of either estrogen replacement therapy or estrogen and progestin combination therapy for a cumulative duration of 3 months or more. A subject was defined to be with contraceptive use if she had a history of contraceptive medication for a cumulative duration of 3 months or more. If the subject was a current user, the cumulative duration of use would be calculated from the time between the age of initiation and the age when the subject was included.
Passive cigarette smoking was defined by inhaling other people's cigarette smoke at the workplace, or by living with family members who smoked. The body mass index (BMI; kg/m 2 ) was calculated from the body height (meters) and weight (kilograms). The body weight of healthy controls was obtained at enrollment. To avoid underestimating the BMI due to cancer-related body weight loss, the body weight of the cases was recorded according to the value while the case was in a healthy state. The body weight was recorded according to the patients' statement at enrollment.
Exposure to cooking fumes was defined by continuous cooking for at least 6 months. The cumulative dose of cooking fume exposure (cooking time-years) was calculated by multiplying the duration of cooking (years) by cooking intensity (times per day). A family history of breast, ovary, cervix or endometrial cancers in first-degree female relatives was recorded. The history of oophorectomy was also recorded.
Genotyping analysis
Genomic DNA was extracted from blood samples by a conventional phenol-chloroform extraction method. Previously, we have conducted a GWAS using the Illumina HumanHap610 Quad BeadChip on contract at deCODE Genetics in Iceland to identify SNPs associated with lung adenocarcinoma risk for never-smoking women in a case-control study (29) . In the GWAS, 550 cases and 549 controls were genotyped. After genotyping, quality control metrics were conducted. SNPs were excluded if (i) the call rate was below 90%, (i.e. a missing rate larger than 0.1); (ii) SNPs with a minor allele frequency below 5%; (iii) SNPs had a missing rate between 0.02 and 0.1 and non-random genotype failure with P < 0.02, and significant deviation from fitness from the Hardy-Weinberg Equilibrium (P < 0.0001 in controls). In addition, 12 individuals were also excluded based on the population substructure. Consequently, 532 cases and 532 controls with 457,504 SNPs passed quality control. The EGFR SNPs passing the quality control were retrieved from the GWAS data. A total of 84 EGFR SNPs were retrieved from the GWAS data and analyzed. SNP genotyping data from the 532 cancer-free controls were uploaded to Haploview 4.2 to define linkage disequilibrium (LD) patterns (32) .
Statistical analysis
Variables including education, passive smoking status, menopausal status, number of pregnancies, deliveries and miscarriages, HRT use and contraceptive medication, family history of certain malignancies and history of exposure to cooking fumes were investigated. The differences between the case and control groups were analyzed by Pearson's chi-square test. The variables with significant difference between case and control groups were selected for adjustment in multivariate analysis.
To explore the interaction between the EGFR polymorphisms and HRT use for the risk of lung adenocarcinoma, we designed a strategy (Supplementary Figure 1 , available at Carcinogenesis Online) based on the previous study on SNPs of specific locus and lung cancer risk by Pande et al. (33) . First, we performed a test of interaction between each of the 84 retrieved SNP and HRT use by including the first-order interaction term together with the mains effects into the multivariate logistic models with adjustment of covariates of statistical significance found in the univariate analyses. Only those SNPs with a P value < 0.06 for the test of the first-order interaction term were included in the second stage of analysis, so as to avoid missing the SNPs at a marginal significance, which may potentially interact with HRT use.
Next, to filter out highly correlated SNPs, Tagger, a program implemented within Haploview was used to select tagging SNP. This step was to capture SNPs that were in high LD with each other at an r 2 ≥ 0.95. We also conducted separate logistic regression analyses testing genotypic effects within different stratums of HRT with adjustment of covariates to identify the high-risk genotype for each selected tagging SNP.
Third, all selected tagging SNPs were then moved further for constructing the haplotype blocks by Haploview. The algorithm used by Haploview is taken from the report in 2002 (34) . Ninety-five percent confidence bounds on D′ are generated and each comparison is called 'strong LD,' 'inconclusive' or 'strong recombination.' A block is created if 95% of informative (i.e. non-inconclusive) comparisons are 'strong LD.' Subsequently, we assessed the cumulative effect of the putative high-risk SNPs genotypes for each haplotype block on lung adenocarcinoma risk, with adjustments of covariates. 
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The SAS system for Windows version 8.2 (SAS Institute, Cary, NC) was used for statistical analysis. All statistical tests were two sided. Except for the selection of potential SNPs interacting with HRT use in association with lung adenocarcinoma risk, a P value < 0.05 was considered to be statistically significant. We applied the Benjamini and Hochberg method to control the false discovery rate at a level of 0.05, so as to reduce the effect of multiple testing (35) . The bootstrap was used for internal model validation (36) . More specifically, a bootstrap SAS Macro developed by P.Johnson (37) was used to calculate bootstrap estimates of odds ratios (OR) in logistic regression. For each bootstrap estimate of OR, 10,000 bootstrap replications were carried out.
Results

Clinical characteristics
Subjects, including 532 lung adenocarcinoma patients and 532 healthy controls, were recruited from September 2002 to December 2009. As shown in Table I , a significant difference between patients and controls was observed for the proportion of HRT use (25.38% versus 31.57%, P = 0.028). There were also significant differences between the patients and controls in educational level (P = 0.017), passive smoking (P = 0.022) and period of cooking fume exposure (P = 0.003), which were adjusted in the multivariate analysis. No significant differences were found between patients and controls in age, BMI, menopause, contraceptive medicine use, miscarriage, pregnancy, delivery, oophorectomy and family history of breast, ovarian, cervical or endometrial cancers.
Analysis of EGFR SNPs retrieved from GWAS data
Among the 84 SNPs retrieved, rs17746482, rs7809332, rs940810, rs4947995 and rs11767730 were associated with lung adenocarcinoma risk, without adjusting for multiple comparison effects (P values Figure 1 , available at Carcinogenesis Online). A test of interaction between each SNP and HRT use was performed by including the first-order interaction term, together with the main effects into the multivariate logistic models, with adjustment for other covariates including educational level, passive smoking and cooking fume exposure. Thirteen SNPs were considered as potentially interacting with HRT use in association with lung adenocarcinoma risk. The largest P value was 0.0587 (Table II) .
Using Haploview program to select tagged SNP at an r 2 threshold of ≥0.95 to filter out highly correlated SNPs, we found 11 tagging SNPs out of the 13 SNPs. Two haplotype blocks, block 1 and block 2, were constructed to identify sets of SNP in LD among the 11 tagging SNPs. Three SNPs rs7776830, rs12536061 and rs7809332 are located at the block 1, whereas five SNPs rs4245566, rs4947995, rs17746482, rs12535482 and rs11767730 are located at the block 2 ( Figure 1 ). The frequency of genotypes for each EGFR SNP in the two haplotype blocks from all the subjects was shown in Supplementary Table 2, available at Carcinogenesis Online. In subjects without HRT use, rs7809332 (AA + AG) (OR: 1.784, 95% CI: 1.180-2.699) and rs17746482 (AA + AG) (OR: 1.916, 95% CI: 1.087-3.375) were associated with a significantly increased risk of lung adenocarcinoma.
Interaction between EGFR SNPs and HRT use
Among these EGFR SNPs, rs7776830, rs12536061, rs7809332, rs4245566, rs4947995, rs17746482, rs12535482 and rs11767730 showed a significant or borderline significant interaction with HRT use in association with lung adenocarcinoma risk (P values for interactions are 0.0032, 0.0587, 0.0104, 0.0462, 0.0016, 0.0515, 0.0587 and 0.0130, respectively).
The cumulative effects of EGFR SNP genotypes on lung adenocarcinoma risk
We assessed the cumulative effect of the putative protective EGFR SNP genotypes on the lung adenocarcinoma risk for each haplotype block, with adjustments of covariates. For block 1, subjects with HRT use carrying CA or CC genotype of rs7776830, AA genotype of rs12536061 and AA or AG genotype of rs7809332 were considered as protective, whereas for block 2, subjects with HRT use carrying GG genotype of rs4245566, GA or GG genotype of rs4947995, AA or AG genotype of rs17746482, GG genotype of rs12535482 and AA or AG genotype of rs11767730 were considered as protective.
Table IV illustrated the cumulative effects on lung adenocarcinoma risk for subjects with increasing number of SNP genotypes. There is a significant interactive effect of HRT use with numbers of protective EGFR SNPs on the risk of lung adenocarcinoma in blocks 1 and 2 (P for interaction = 0.0004 and 0.0032, respectively). A trend of decreased risk to develop lung adenocarcinoma was found in subjects with HRT use harboring an increasing number of protective EGFR SNPs genotypes for blocks 1 and 2 (P for trend = 0.0032 and 0.0046, respectively). The trend of increase risk was not significant in subjects without HRT use. The Benjamini and Hochberg method for the adjustment of multiple comparisons was applied to all the tests for interaction and to the tests for trend in risk change with respect to HRT use. The bootstrap analysis was performed for internal validation. As shown in Supplementary Table 4, available at Carcinogenesis Online, all the bootstrap estimates of ORs are very close to those estimates from multivariate models.
More specifically, subjects with HRT use carrying two protective genotypes had a significantly lower risk to develop lung adenocarcinoma than subjects carrying no high-risk genotypes in block 1 (OR: 0.326, 95% CI: 0.182-0.584). In contrast, for block 2, subjects with HRT use carrying four protective genotypes had a significantly lower lung adenocarcinoma risk than subjects carrying no protective genotype (OR: 0.239, 95% CI: 0.107-0.536). In both haplotype blocks, we can see that EGFR SNPs could have a cumulative effect on decreasing lung adenocarcinoma risk for subjects with HRT use, but not for subjects without HRT use.
Positions and functional locations of EGFR SNPs that interact with HRT use
The positions and functional locations of 11 tagged SNPs interacting with HRT were listed in Supplementary Table V, available at Carcinogenesis Online. These SNPs are mostly located near the tyrosine kinase (TK) domain of EGFR (Figure 2) . The SNP rs11977660 is located in the intron 1, rs845562 in intron 19 and rs940810 in the 3′ untranslated region. The other SNPs in block 1 (rs7776830, rs12536061, rs7809332) and block 2 (rs4245566, rs4947995, EGFR SNP, HRT and lung adenocarcinoma risk rs17746482, rs12535482, rs11767730) are located in the 3′ untranslated region.
Discussion
Our study demonstrates the interaction between EGFR SNPs and HRT use in association with lung adenocarcinoma risk in neversmoking women. These SNPs were mostly located near the EGFR TK domain. In subjects with HRT use, there is a trend of decrease in lung adenocarcinoma risk while harboring an increasing number of protective genotypes of EGFR SNPs.
There is a trend of increase for lung cancer in never smokers in developed countries (38, 39) . The smoking rates in Asian women are lower than in European and American women (40) , raising the importance of studies on lung cancer risk in never smokers, especially in Asia. Some environmental risk factors for never smokers have been demonstrated, including second-hand smoking, cooking fumes exposure, endogenous and exogenous hormone exposure, occupational exposure, radon exposure, preexisting lung diseases and human papilloma virus infection (41, 42) . The association between genetic variation and lung cancer risk has been extensively reported (43) (44) (45) (46) (47) (48) (49) . However, most subjects were smokers in these studies. The evaluation of lung cancer risk in never smokers is difficult because of the relatively small subset populations. Therefore, we recruit never-smoking women from a large-scale epidemiological study population. More studies on the association of genetic variations and lung cancer, with respect to never smokers, might be warranted.
Lung carcinogenesis may result from the interactions between genetic alterations and environmental factors. The study by Ito et al. (50) showed a significant interaction between smoking status and APE1 gene for lung cancer. We have also demonstrated an interactive effect of cigarette smoking with hOGG1 polymorphisms on the risk of lung cancer (51) . The interactions with opposite effects in subject groups with and without exposure will make the main effect difficult to be identified. In this study, we further target on two putative risk factors, EGFR polymorphism and HRT, for the never-smoking subjects and try to clarify the interaction between these factors. The studies on the relationship between EGFR polymorphisms and HRT may be helpful to find more high-risk population groups and provide better insight into the crosstalk of EGFR and estrogen receptor pathway mechanism in lung cancer.
Genome-wide association scan is usually used to search for the SNPs or cluster of SNPs associated with diseases, with an extremely low P value (52, 53) . For complex diseases that may result from geneenvironmental interaction, scanning for main effects by GWASs might miss important genetic variants specific to subgroup population with certain environmental exposure. In the recent years, GWASs were applied for researches of lung carcinogenesis (54) (55) (56) (57) (58) (59) (60) . These studies identified susceptibility variants located on chromosome 15p25, 5p15 and 6p21. The subjects of these studies were mainly current or ex-smokers. A more recent GWAS focused on never smokers identified that genetic variants at 13q31.3 alter the expression of GPC5 and are associated with susceptibility to lung cancer (61). There might be susceptibility alleles for lung cancer masked by heterogeneity in subgroups with different environmental exposures. Analyzing GWASs data with environmental exposure information may identify these masked genetic variants and clarify whether environmental exposures may modify cancer risk in individuals harboring certain gene polymorphisms. However, few studies have explored the gene-environment interaction in GWASs. This is the first study on interaction between gene SNPs and HRT use for lung cancer risk. We found EGFR SNPs interact with HRT use, with a cumulative effect on decreased lung adenocarcinoma risk in subjects with HRT use. Our study supports the hypothesis that the inconsistent findings in previous studies on HRT use and female lung carcinoma risk may be, at least partly, due to the genetic variation among subjects groups. In addition, the SNPs were mostly located in the intron 19 and 3′ untranslated region, which are near the EGFR TK domain. For non-small cell lung carcinoma with exon 19 in-frame deletion and L858R mutation in the TK domain of EGFR, good treatment response to EGFR inhibitors and prolonged progression-free survival were reported (62) (63) (64) . A case-control study on Taiwanese subjects found functional EGFR germline polymorphisms may confer risk for the occurrence of EGFR mutations in non-small cell lung carcinoma, with a predominant effect on exon 19 microdeletions (65) . Our recent study showed that the L858R mutation in EGFR is associated with polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients (66) . Few studies investigated the association of the SNPs in the EGFR TK domain and lung cancer risk. Our findings indicate that SNPs, which interact with HRT use, may have a correlation with the TK domain of EGFR. These SNPs were not reported to be functional in previous studies. Further studies on their possible roles in interaction with EGFR and estrogen pathways are warranted.
Our study is a secondary analysis from a molecular epidemiological study on susceptibility markers of lung cancer. The number of female never-smoking patients with lung adenocarcinoma is limited. Because lung cancer is a heterogeneous disease with various histologic types and different etiologies, a tradeoff between increase of sample size and heterogeneity of study population should be considered. Thus, we recruit never-smoking lung adenocarcinoma patients and healthy controls to improve the homogeneity of study population. These findings may need to be interpreted carefully and validated in further large population-based studies.
In conclusion, HRT use may modify the association of EGFR SNPs with lung adenocarcinoma risk. EGFR SNPs could have a cumulative effect on decreasing lung adenocarcinoma risk for never-smoking women with HRT use.
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